CN1616069A - Ginkgo medicine composition, its preparing method and its use - Google Patents

Ginkgo medicine composition, its preparing method and its use Download PDF

Info

Publication number
CN1616069A
CN1616069A CN 200410083882 CN200410083882A CN1616069A CN 1616069 A CN1616069 A CN 1616069A CN 200410083882 CN200410083882 CN 200410083882 CN 200410083882 A CN200410083882 A CN 200410083882A CN 1616069 A CN1616069 A CN 1616069A
Authority
CN
China
Prior art keywords
ginkgo
folium ginkgo
medicine composition
extract
folium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200410083882
Other languages
Chinese (zh)
Other versions
CN1320890C (en
Inventor
王建辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong ho Pharmaceutical Company Limited
Original Assignee
Faires Duke Pharmaceutical (tonghua) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faires Duke Pharmaceutical (tonghua) Co Ltd filed Critical Faires Duke Pharmaceutical (tonghua) Co Ltd
Priority to CNB2004100838829A priority Critical patent/CN1320890C/en
Publication of CN1616069A publication Critical patent/CN1616069A/en
Application granted granted Critical
Publication of CN1320890C publication Critical patent/CN1320890C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The gingko medicine composition consists of gingko leaf extract and ligustrazine phosphate in the amount of 1-100 times of gingko leaf extract. The preparation process of the medicine composition is also disclosed. As the compound preparation, the medicine composition of the present invention has the complementary and synergistic effects of gingko leaf extract and ligustrazine phosphate, including promoting blood circulation to disperse blood clots, resisting platelet aggregation, dilating blood vessel and improving microcirculation, and may be used in preparing medicine for ischemic cardiac and cerebral vascular diseases.

Description

A kind of ginkgo medicine composition, Its Preparation Method And Use
Technical field
The present invention relates to a kind of pharmaceutical composition, Its Preparation Method And Use, specifically, relate to a kind of pharmaceutical composition that combines by ligustrazine phosphate and the Folium Ginkgo extract that from Folium Ginkgo, extracts, its preparation method and the application aspect preparation treatment ischemic cardio cerebrovascular diseases medicine thereof.
Background technology
Contain active ingredients such as total flavones, total lactone in the Folium Ginkgo extract, total flavones is the main active of Folium Ginkgo extract.The content of total flavones in Folium Ginkgo is 0.5%～1% (W/W), mainly exists with the glycoside form, and main glycoside unit is Quercetin, kaempferol and isorhamnetin.The contained Ginkgo total flavones of Folium Ginkgo extract has dilating coronary blood vessel, cerebrovascular, blood circulation promoting and blood stasis dispelling, improves symptom and memory function that cerebral ischemia produces.Folium Ginkgo extract all has improvement to cerebral thrombus patient's cerebral circulation, glucose metabolism, breathing, and functional central nervous system injury is had therapeutical effect.The clinical ischemic cardio cerebrovascular diseases that is usually used in of Folium Ginkgo extract, angina pectoris, cerebral embolism, cerebral vasospasm etc.
Ligustrazine phosphate is 2 phosphate monohydrate (C 8H 12N 2H 3PO 4H 2O),, have antiplatelet aggregative activity, and accumulative platelet is had depolymerisation, expansion small artery, microcirculation improvement, cerebral blood flow increasing and function of promoting blood circulation to disperse blood clots for white or off-white color crystalline powder.Ligustrazine phosphate absorbs and drains rapidly, can pass through blood-CSF barrier.The clinical ischemic cerebrovascular (as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism) that is used for.
99100263.6 disclose a kind of pharmaceutical composition for the treatment of cerebrovascular, this pharmaceutical composition contains ligustrazine hydrochloride 15～30%, Radix Notoginseng total arasaponins 40～60%, Semen Ginkgo extrac 15～40%.This pharmaceutical composition proves a kind of action temperature and persistent medicine through pharmacology, toxicological experiment, can strengthen anti-stress and endurance, can effectively prevent the formation of tampon, promotes the meninges microcirculation, blood flow increasing, and the control local cerebral ischemia improves motor behavior.
But at present, after still no-trump Folium Ginkgo extract and ligustrazine phosphate carry out assembly with certain proportion, make the report that medicine carries out clinical use.
Summary of the invention
The object of the present invention is to provide a kind of ginkgo medicine composition, said composition is the compound preparation that Folium Ginkgo extract and ligustrazine phosphate form by the special ratios assembly.
Another object of the present invention is to provide a kind of preparation method of ginkgo medicine composition.
A further object of the present invention is to provide a kind of preparation treatment ischemic cardio cerebrovascular diseases, as the application of cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vasospasm, brain insufficiency, alzheimer disease, parkinson, apoplexy, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris, each disease medicament aspect of myocardial infarction.
Another purpose of the present invention is to provide a kind of prepare the microcirculation pathological changes that treatment hepatic fibrosis, diabetes cause, the application of each disease medicament aspect of vasculitis.
Contain ligustrazine phosphate (C in the ginkgo medicine composition of the present invention 8H 12N 2H 3PO 4H 2O) and the Folium Ginkgo extract that from Folium Ginkgo, extracts (in Ginkgo total flavones), contained ligustrazine phosphate weight is 1～100 times of Folium Ginkgo extract (in Ginkgo total flavones) weight in the pharmaceutical composition.
Further, in the ginkgo medicine composition of the present invention ligustrazine phosphate weight be Folium Ginkgo extract (in Ginkgo total flavones) weight preferably be 5～50 times, more preferably 5～20 times, most preferred is 10 times.
Weight portion of the present invention can be the known content units of field of medicaments such as μ g, mg, g, kg.
Ginkgo medicine composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, therefore can use said composition also can contain one or more adjuvant; Such as sodium chloride, starch, Pulvis Talci and magnesium stearate etc., the acceptable adjuvant of pharmaceutical field.
Ligustrazine phosphate of the present invention can adopt the raw material that meets medicinal standard.
Described Folium Ginkgo extract is that the dried leaves of Ginkgoaceae plant Ginkgo biloba is prepared from through extraction.
The preparation method of ginkgo medicine composition of the present invention is: earlier Folium Ginkgo is extracted, the Folium Ginkgo alcohol reflux, the extracting solution thickening filtration, resin absorption, eluting, reconcentration is drying to obtain Folium Ginkgo extract, then Folium Ginkgo extract and ligustrazine phosphate is carried out proportioning and mixes, and adds the compositions that pharmaceutically acceptable adjuvant is made acceptable various dosage forms on the pharmaceutics again.
Specifically, the Folium Ginkgo extract preparation process is:
After Folium Ginkgo is pulverized, adds 8～12 times and measure 60～75% ethanol, twice of 40～50 ℃ of reflux, extract,, each 2～5 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/12, the water that adds 1～2 times of concentrated liquid measure, the reuse addition is that 1～2% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 60～75% alcoholic solution desorbings, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
Its preparation process is preferably: after Folium Ginkgo is pulverized, adds 8～12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 2～4 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/10, the water that adds 1 times of concentrated liquid measure, the reuse addition is that 1% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 70% alcoholic solution desorbing, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
Described filter aid can be sodalite or Pulvis Talci.
Described macroporous resin can be D101 type resin or HP-20 type resin.
During desorbing, the addition of used alcoholic solution is 2～3 times of adsorbent resin amount.
Certainly, in the preparation process of ginkgo medicine composition of the present invention, also can directly adopt the commercially available Folium Ginkgo extract that meets the national drug standards.
Ginkgo medicine composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, and as lyophilized injectable powder, tablet, capsule, small-volume injection, bulk capacity injection, preferred dosage form is small-volume injection, bulk capacity injection.The various dosage forms of ginkgo medicine composition of the present invention can be according to the conventional production method preparation of pharmaceutical field.Such as using ligustrazine phosphate, Folium Ginkgo extract to mix, be made into required dosage form then with one or more carriers.
Ginkgo medicine composition of the present invention needs to add an amount of sodium chloride as isoosmotic adjusting agent when being prepared into bulk capacity injection.
Research worker of the present invention is tested discovery in a large number, ligustrazine phosphate (C in ginkgo medicine composition 8H 12N 2H 3PO 4H 2Synergism was best when O) weight was 10 times of proportionings of Folium Ginkgo extract (in Ginkgo total flavones) weight, curative effect is best.
The present invention most preferably specification of ginkgo medicine composition bulk capacity injection is the 250ml/ bottle, and every bottle contains ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg.
Usage is as follows: intravenous drip, one time one bottle, 10～15 days is a course of treatment.
Ginkgo medicine composition of the present invention replenishes synergism mutually by Folium Ginkgo extract and ligustrazine phosphate, can play beyond thought effect.Contain effective ingredient such as Ginkgo total flavones, Ginkgo total lactones in the Folium Ginkgo extract of the present invention.Ginkgo total flavones has obvious blood fat reducing, cholesterol reducing effect, increase the coronary blood liquid measure, reduce myocardial oxygen consumption, microcirculation improvement, have and improve symptom and the memory function that cerebral ischemia produces, cerebral circulation, glucose metabolism, breathing to the cerebral thrombosis person all have improvement, and functional central nervous system injury is had therapeutical effect.Bilobalide has anticoagulation, reduces blood viscosity, improves blood flowing characteristic, prevents thrombosis, promotes thrombolytic effect.Ligustrazine phosphate has antiplatelet aggregative activity, and accumulative platelet is had depolymerisation, can expand small artery, and microcirculation improvement, cerebral blood flow increasing and function of promoting blood circulation to disperse blood clots are arranged.Ligustrazine phosphate absorbs and drains rapidly, can play a role by blood-CSF barrier.
Ginkgo medicine composition of the present invention is the compound preparation that Folium Ginkgo extract and ligustrazine phosphate form by the special ratios assembly, and its absorption and drainage can be passed through blood-cerebrospinal fluid barrier rapidly.By the two additional mutually body that acts synergistically on, give full play to blood circulation promoting and blood stasis dispelling, anti-platelet aggregation is arranged, blood vessel dilating, the microcirculation improvement effect, the smelting that is applicable to ischemic cardio cerebrovascular diseases is treated, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vasospasm, brain insufficiency, alzheimer disease, parkinson, apoplexy, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris, myocardial infarction.Also can be used for the microcirculation pathological changes that hepatic fibrosis, diabetes cause, vasculitis etc.
The specific embodiment
Further describe the present invention with embodiment below, help understanding, but described embodiment only is used to illustrate the present invention rather than restriction the present invention the present invention and advantage thereof, better effects if.
Embodiment 1
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/10, the water that adds the equivalent concentrated solution, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 70% alcoholic solution desorbing of 2 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 16g (containing total flavones 4g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 40g can be made into the 100000ml medicinal liquid, finally makes 400 bottles of bulk capacity injections (specification is the 250ml/ bottle).In dense preparing tank, add an amount of 85 ℃ of waters for injection, in dense preparing tank, drop into 900g sodium chloride, fully stir and make dissolving fully, add active carbon by 0.04% of preparation cumulative volume, heat 90 ℃, be incubated 20 minutes, be cooled to 50 ℃, the medicinal liquid decarbonization filtering to dilute preparing tank, is added ligustrazine phosphate and Folium Ginkgo extract in dilute preparing tank, fully stir and make dissolving fully, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, and added water for injection to the dosing amount, transferring PH is 4.8 ± 0.2, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, and embedding is filled nitrogen by bottle during embedding in infusion bottle, sterilization promptly gets infusion products.
Embodiment 2
After Folium Ginkgo 5000g pulverizes, add 10 times of amount 65% ethanol, twice of 45 ℃ of reflux, extract,, each 4 hours, merge extractive liquid,, filter, be evaporated to extracting liquid volume 1/8, the water that adds 1.5 times of concentrated liquid measures, add the 2% Pulvis Talci filter aid that concentrates liquid measure and filter, filtrate is with macroporous resin (as HP-20 type resin) absorption, with 72% alcoholic solution desorbing of 3 times of amounts of macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 50g can be made into the 2000ml medicinal liquid, finally makes 1000 of small-volume injections.In preparing tank, add an amount of 48 ℃ of waters for injection, add ligustrazine phosphate and Folium Ginkgo extract again, fully stir and make dissolving fully, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, and added water for injection to the dosing amount, transferring PH is 4.5, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, and embedding is in ampoule, and ampoule fills nitrogen by propping up during embedding, sterilization promptly gets small-volume injection.
Embodiment 3
After Folium Ginkgo 5000g pulverizes, adds 10 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/9, add 2 times of concentrated solution water gagings, add the 1.5% Pulvis Talci filter aid that concentrates liquid measure and filter, filtrate is with macroporous resin (as D101 type resin) absorption, with 70% alcoholic solution desorbing of 2 times of amounts of macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 200g can be made into the 1000ml medicinal liquid, finally makes 1000 of small-volume injections.Add an amount of 48 ± 2 ℃ of waters for injection in preparing tank, add ligustrazine phosphate and Folium Ginkgo extract again, fully stirring is dissolved it fully, add the Dextran 40 excipient, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, add water for injection to the dosing amount, transferring PH is 4.8, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, medicinal liquid fill behind end-filtration (loading amount 1.0ml/ props up), the freeze-dried powder product is made in lyophilizing behind the false add plug.
Embodiment 4
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8, the water that adds the equivalent concentrated solution, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 70% alcoholic solution desorbing of 3 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 100g can finally make 1000 in tablet.Will Folium Ginkgo extract, ligustrazine phosphate mixes with 80 gram starch mixings after granulate with starch slurry, cross 20 mesh sieve granulate, drying adds 1 gram magnesium stearate compacting in flakes, promptly gets the ginkgo medicine composition tablet.
Embodiment 5
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 60% ethanol, twice of 50 ℃ of reflux, extract,, each 2 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/11, the water that adds 2 times of concentrated liquid measures, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 65% alcoholic solution desorbing of 3 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 2g can finally make capsule.Behind Folium Ginkgo extract, ligustrazine phosphate and 80 gram starch, 80 gram Pulvis Talci mixings, cross 100 mesh sieves, encapsulated, get the ginkgo medicine composition capsule.
Embodiment 6
The extraction process of Folium Ginkgo extract is with embodiment 1, and different is Folium Ginkgo extract 16g (containing total flavones 4g), ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) 20g.
Experimental example 1
(every bottle contains ligustrazine phosphate (C to this experimental example for the most preferred ginkgo medicine composition bulk capacity injection of the present invention 8H 12N 2H 3PO 4H 2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) detection of injection inspection item of appearance character, pH value, heavy metal and other regulation.
√ character this product is that little yellow is to lurid clear liquid.
√ pH value pH value should be 3.5-5.5 (two appendix VI of Chinese Pharmacopoeia version in 2000).
√ heavy metal precision is measured this product 25ml, puts in the crucible, and water bath method is checked (two appendix VIII of Chinese Pharmacopoeia version in 2000 H, second method) in accordance with the law, contains heavy metal and must not cross 5/1000000ths.
The √ pyrogen: get this product, check (two appendix XI of Chinese Pharmacopoeia version in 2000 D) in accordance with the law, dosage is slowly injected 10ml by the every 1kg of rabbit body weight, should be up to specification.
√ other: should meet under the injection item relevant every regulation (2000 editions two appendix IB of Chinese Pharmacopoeia).
Experimental example 2
(every bottle contains ligustrazine phosphate (C to this experimental example for of the present invention most preferred ginkgo medicine composition bulk capacity injection 8H 12N 2H 3PO 4H 2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) in the qualitative determination of key component.
Get this product 2ml, add 2 of bismuth potassium iodides, promptly generate salmon precipitation.
In the chromatogram that writes down under Ginkgo total flavones and ligustrazine phosphate assay item, the retention time at test sample peak should be consistent with the corresponding peak of reference substance retention time.
This product shows sodium salt and muriatic identification (two appendix III of Chinese Pharmacopoeia version in 2000).
More than 3 kinds of experiments be the qualitative reactions of the contained component of ginkgo medicine composition of the present invention, illustrate and contain definite component in the ginkgo medicine composition of the present invention.
Experimental example 3
(every bottle contains ligustrazine phosphate (C to this experimental example for the most preferred ginkgo medicine composition bulk capacity injection of the present invention 8H 12N 2H 3PO 4H 2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) in the detection by quantitative of component.Every ml contains the Semen Ginkgo total flavones and should be 36-44 μ g, ligustrazine phosphate (C 8H 12N 2H 3PO 4H 2O) should be 0.36-0.44mg.
Ginkgo total flavones alcohol glycoside (Ginkgo total flavones) assay is measured according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; With methanol-0.4% phosphoric acid (55: 45) is mobile phase; The detection wavelength is 368nm.Number of theoretical plate calculates by the Quercetin peak should be not less than 2500, and separating degree presses Quercetin and the isorhamnetin peak calculates, should be greater than 1.5.
The preparation precision of reference substance solution takes by weighing through the exsiccant Quercetin of phosphorus pentoxide, kaempferol and isorhamnetin reference substance, adds methanol and makes the mixed solution that every 1ml contains 0.03mg, 0.03mg, 0.02mg, in contrast product solution.
The preparation precision of need testing solution is measured this product 100ml, 50 ℃ are evaporated to about 5ml, add methanol 8ml, 18% hydrochloric acid 3ml, put in the water-bath reflux 1.5 hours, and be cooled to room temperature rapidly, move in the 25ml measuring bottle, add methanol and be diluted to scale, shake up, filter through filter membrane (aperture must not greater than 0.45 μ m), as need testing solution.
Accurate respectively reference substance solution and each the 20 μ l of need testing solution of drawing of algoscopy inject high performance liquid chromatograph, measure, and calculate the content of three kinds of glycosides millions respectively, are converted into the content of total flavones alcohol glycoside with following formula.
Total flavones alcohol salidroside content=(quercetin content+kaempferol content+isorhamnetin content) * 2.51
The ligustrazine phosphate assay is measured according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With methanol-water (50: 50) is mobile phase; The detection wavelength is 295nm.Number of theoretical plate calculates by the ligustrazine phosphate peak should be not less than 2000.
Algoscopy is got this product, adds the mobile phase dissolving and is diluted to the solution that contains 20 μ g among every 1ml, gets 20 μ l and injects chromatograph of liquid, the record chromatogram; It is an amount of that other gets the ligustrazine phosphate reference substance, measures with method, presses external standard method with calculated by peak area.
By three batches of mensuration, every ml content results sees Table 1:
Table 1
Lot number Ginkgo total flavones (μ g) Ligustrazine phosphate (mg)
????20030701 ?39.0 ??0.41
????20030702 ?38.2 ??0.38
????20030703 ?39.2 ??0.39
Comparative example 1
This example is that (every bottle contains ligustrazine phosphate (C8H12N2H3PO4H2O) 100mg to the most preferred pharmaceutical composition bulk capacity injection of the present invention, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) with separately with YINXINGYE ZHUSHEYE or ligustrazine phosphate injection clinical comparison at treatment ischemic cerebrovascular cerebral infarction, the good efficacy of pharmaceutical composition of the present invention is described, promptly the coordinating effect of ligustrazine phosphate and Folium Ginkgo extract is better than using separately YINXINGYE ZHUSHEYE or ligustrazine phosphate injection.
Matched group 1:32 example, wherein the male is 21 examples, the women is 11 examples.Age 43-72 year, average 57.5 years old.
Matched group 2:32 example, wherein the male is 20 examples, the women is 12 examples.Age 40-70 year, average 56.5 years old.
The ischemic cerebrovascular diagnostic criteria that the equal national cerebrovascular academic conference of all cases is worked out is all made a definite diagnosis through brain CT.
Therapeutic Method:
The most preferred pharmaceutical composition bulk capacity injection of the equal intravenous drip the present invention of treatment group patient injection, one time one bottle, 1 time on the one, treated for 3 weeks;
Matched group 1 patient dilutes YINXINGYE ZHUSHEYE 5ml (containing Semen Ginkgo total flavones 4.2mg and bilobalide 0.3mg) with 5% glucose injection 250ml, and intravenous drip once-a-day, treated for 3 weeks.
Matched group 2 patients dilute ligustrazine phosphate injection 100mg with 5% glucose injection 250ml, and intravenous drip once-a-day, treated for 3 weeks.
In therapeutic process, all look the state of an illness and need give dehydrant, antibiotic for three groups, keep corresponding treatments such as water-electrolyte balance.
Efficacy determination:
Produce effects: symptom and sign disappears substantially or is clearly better, and paralysed limb muscular strength improves more than 2 grades; Effectively: symptom and sign takes a turn for the better, and paralysed limb muscular strength improves 2 grades of less thaies; Invalid: symptom and sign does not have change or increases the weight of.
Therapeutic outcome:
The effective percentage and the curative effect of treatment group and matched group are compared, and two groups of effective percentage of treatment group and matched group are P＜0.01 relatively, and difference has significance, and matched group 1 is not remarkable with matched group 2 differences, the results are shown in Table 2.
Table 2 treatment group and matched group curative effect are relatively
Matched group 1 (n=32) matched group 2 (n=32) treatment group (n=32)
Example numerical example numerical example number
Produce effects 13 13 23
Effective 12 13 8
Invalid 761
Effective percentage 78.1 81.3 96.9
Annotate: two groups of curative effects compare p＜0.01
Comparative example 2
This example is that (every bottle contains ligustrazine phosphate (C8H12N2H3PO4H2O) 100mg to the most preferred pharmaceutical composition bulk capacity injection of the present invention, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) with the clinical efficacy contrast of YINXINGYE ZHUSHEYE at the treatment angina pectoris, the good efficacy of pharmaceutical composition of the present invention is described, promptly the coordinating effect of ligustrazine phosphate and Folium Ginkgo extract is better than using separately YINXINGYE ZHUSHEYE (SHUXUENING ZHUSHEYE).
Clinical settings: coronary heart disease with qi deficiency and blood stasis patient with angina pectoris Patients with Cerebral Infarction 90 examples are divided into treatment group and matched group at random.
60 examples are organized in treatment, male 34 examples, women 26 examples, 40～72 years old age, average 58 years old;
Matched group 30 examples, wherein the male is 21 examples, the women is 9 examples.Age 39-68 year, average 55.3 years old.
All cases all meet national internal medicine meeting cardiovascular special interest group angina pectoris diagnostic criteria and Chinese medical discrimination syndrome of deficiency of heart qi and blood stasis type standard.
Therapeutic Method:
The most preferred pharmaceutical composition bulk capacity injection of the equal intravenous drip the present invention of treatment group patient injection, one time one bottle, 1 time on the one, treated 20 days;
The matched group patient dilutes YINXINGYE ZHUSHEYE 5ml (containing Semen Ginkgo total flavones 4.2mg and bilobalide 0.3mg) with 5% glucose injection 250ml, and intravenous drip once-a-day, was treated 20 days.
Efficacy determination:
Produce effects: transference cure or basic the disappearance, electrocardiogram recovers normally or is roughly normal; Effectively: the angina pectoris attacks number of times obviously reduces, and degree obviously alleviates, and the persistent period obviously shortens, and ECG ST section reduces, more than rise 0.5mv after the treatment, the negative T wave that mainly leads shoal (reaching more than 25%) or by smooth for upright; Invalid: symptom and electrocardiogram do not have change.
Therapeutic outcome:
Treatment group produce effects 34 examples, effective 22 examples, invalid 4 examples, total effective rate is 93.33%; Matched group produce effects 10 examples, effective 13 examples, invalid 7 examples, total effective rate 76.66%.Two groups of total effective rates compare, and difference has significance meaning (P＜0.05).The electrocardiogram total effective rate: treatment group 60%, matched group does not relatively have significance meaning P＞0.05 for 53.33%, two group).Hemorheology: treatment group treatment back whole blood viscosity, plasma viscosity, packed cell volume, the every index of Fibrinogen all obviously descend, and the every index of matched group all also has certain decline, and two groups of comparing differences have significance meaning (P＜0.05).

Claims (10)

1. ginkgo medicine composition, it is characterized in that, the Folium Ginkgo extract that contains ligustrazine phosphate and from Folium Ginkgo, extract, contained ligustrazine phosphate weight is 1～100 times of Folium Ginkgo extract weight in the pharmaceutical composition, Folium Ginkgo extract is in Ginkgo total flavones.
2. ginkgo medicine composition according to claim 1, it is characterized in that ligustrazine phosphate weight is 5～50 times of Folium Ginkgo extract weight in the ginkgo medicine composition, more preferably 5～20 times, most preferred is 10 times, and Folium Ginkgo extract is in Ginkgo total flavones.
3. method for preparing any one described ginkgo medicine composition of claim 1～2, it is characterized in that, comprise the steps: earlier Folium Ginkgo to be extracted, the Folium Ginkgo alcohol reflux, extracting solution thickening filtration, resin absorption, eluting, reconcentration is drying to obtain Folium Ginkgo extract, then Folium Ginkgo extract and ligustrazine phosphate is carried out proportioning and mixes, and adds the compositions that pharmaceutically acceptable adjuvant is made acceptable various dosage forms on the pharmaceutics again.
4. ginkgo medicine composition preparation method according to claim 3 is characterized in that, the concrete preparation process of described Folium Ginkgo extract is:
After Folium Ginkgo is pulverized, adds 8～12 times and measure 60～75% ethanol, twice of 40～50 ℃ of reflux, extract,, each 2～5 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/12, the water that adds 1～2 times of concentrated liquid measure, the reuse addition is that 1～2% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 60～75% alcoholic solution desorbings, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
5. according to claim 3 or 4 described ginkgo medicine composition preparation methoies, it is characterized in that the concrete preparation process of described Folium Ginkgo extract is:
After Folium Ginkgo is pulverized, adds 8～12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 2～4 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/10, the water that adds 1 times of concentrated liquid measure, the reuse addition is that 1% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 70% alcoholic solution desorbing, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
6. according to claim 4 or 5 described ginkgo medicine composition preparation methoies, it is characterized in that described filter aid can be sodalite or Pulvis Talci; Described macroporous resin can be D101 type resin or HP-20 type resin.
7. according to any one described ginkgo medicine composition of claim 1～6, it is characterized in that, described compositions can be prepared into the available dosage form on the various pharmaceuticss, as lyophilized injectable powder, tablet, capsule, small-volume injection, bulk capacity injection, preferred dosage form is small-volume injection, bulk capacity injection.
8. ginkgo medicine composition according to claim 7 is characterized in that described preparation is a bulk capacity injection, contains an amount of sodium chloride in the bulk capacity injection as isoosmotic adjusting agent.
9. treat ischemic cardio cerebrovascular diseases according to any one described ginkgo medicine composition of claim 1～8 as preparation, as the application of cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vasospasm, brain insufficiency, alzheimer disease, parkinson, apoplexy, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris, each disease medicament aspect of myocardial infarction.
10. the microcirculation pathological changes that causes as preparation treatment hepatic fibrosis, diabetes according to any one described ginkgo medicine composition of claim 1～8, the application of each disease medicament aspect of vasculitis.
CNB2004100838829A 2003-10-28 2004-10-21 Ginkgo medicine composition, its preparing method and its use Active CN1320890C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100838829A CN1320890C (en) 2003-10-28 2004-10-21 Ginkgo medicine composition, its preparing method and its use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200310102229 2003-10-28
CN200310102229.8 2003-10-28
CNB2004100838829A CN1320890C (en) 2003-10-28 2004-10-21 Ginkgo medicine composition, its preparing method and its use

Publications (2)

Publication Number Publication Date
CN1616069A true CN1616069A (en) 2005-05-18
CN1320890C CN1320890C (en) 2007-06-13

Family

ID=34796275

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100838829A Active CN1320890C (en) 2003-10-28 2004-10-21 Ginkgo medicine composition, its preparing method and its use

Country Status (1)

Country Link
CN (1) CN1320890C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100367963C (en) * 2005-10-28 2008-02-13 阿尔贝拉医药(中国)有限公司 Medicinal composition containing bilobalide B and its preparation process and usage
CN103833650A (en) * 2013-12-12 2014-06-04 吉林长舜制药有限公司 Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1262103A (en) * 1999-01-26 2000-08-09 山东绿叶制药股份有限公司 Chinese-medicinal compound extract for curing cerebrovascular diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100367963C (en) * 2005-10-28 2008-02-13 阿尔贝拉医药(中国)有限公司 Medicinal composition containing bilobalide B and its preparation process and usage
CN103833650A (en) * 2013-12-12 2014-06-04 吉林长舜制药有限公司 Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient
CN103833650B (en) * 2013-12-12 2015-02-25 吉林长舜制药有限公司 Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient

Also Published As

Publication number Publication date
CN1320890C (en) 2007-06-13

Similar Documents

Publication Publication Date Title
CN102038701B (en) Anti-depression application of albiflorin
CN1911257A (en) Extractive of ginkgo tree leaves, prepn. method and application thereof
EP2589382A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
CN101485666B (en) Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor
CN1112198C (en) Thrombolytic medicine and its preparation and use
CN1827112A (en) Dispersion tablet for treating cardiovascular diseases and its preparation method
CN1616069A (en) Ginkgo medicine composition, its preparing method and its use
CN100441195C (en) Medicinal composition containing safflower total flavone and its preparation process and usage
CN100367963C (en) Medicinal composition containing bilobalide B and its preparation process and usage
CN1785216A (en) Medicinal composition contg. total ginkgo flavone, its prepn. method and use
CN1562186A (en) Preparation of Chinese traditional medicine for curing Illness of Cardiac cerebral ischemia and preparation method
CN100404039C (en) Safflower medicine composition and its prepn process and use
CN1939357A (en) Preparation of Ginkgo Damo injection
CN100395261C (en) Compound salt of glycyrrhizin and kurarinol, its production and use
CN1733070A (en) Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process
CN1272026C (en) Medicinal composition for treating cardiocerebral vasculr disease and its preparing method
CN103626709A (en) Ligustrazine phosphate compound and drug composition containing ligustrazine phosphate compound and ginkgo leaf effective ingredients
CN1416880A (en) New use of powder for regulating liver and spleen and its active part
CN104688693A (en) Hydrobromic acid lappaconitine powder-injection pharmaceutical composition for injection and preparation method
CN1177603C (en) Gingko leaf slow-releasing table and preparation process thereof
CN1689637A (en) Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process
CN1771957A (en) Bilobalide-containing medicine composition and its prepn and use
CN1895298A (en) Medicinal preparation for treating and preventing coronary heart disease and thromboembolia disease and its preparation
CN1872051A (en) Dry suspensoid of ginkgolide, and preparation method
CN100577165C (en) Medicinal composition for treating cold wet numbness and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DOBORIPHY PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: AERBERA MEDICINE (CHINA) CO., LTD.

Effective date: 20080912

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080912

Address after: No. 66, Xiangjiang Road, Meihekou, Jilin

Patentee after: Duprofit Pharmacy Company Limited

Address before: Eastern section of North Ring Road, Meihekou, Jilin

Patentee before: Aerbeila Pharmaceutical (China) Co., Ltd.

ASS Succession or assignment of patent right

Owner name: HU NAN QIU ZEYOU PATENT STRATEGIC PLANNING CO., LT

Free format text: FORMER OWNER: QIU ZEYOU

Effective date: 20101028

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 410011 28/F, SHUNTIANCHENG, NO.59, SECTION 2 OF FURONG MIDDLE ROAD, CHANGSHA CITY, HU NAN PROVINCE TO: 410205 JUXING INDUSTRY BASE, NO.8, LUJING ROAD, CHANGSHA HIGH-TECH. DEVELOPMENT ZONE, YUELU DISTRICT, CHANGSHA CITY, HU NAN PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20101105

Address after: 135000 north section of Meihekou, Jilin, Zhujianglu Road

Patentee after: Wansheng Lianhe Pharmaceutical Co., Ltd.

Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin

Patentee before: Duprofit Pharmacy Company Limited

ASS Succession or assignment of patent right

Owner name: MEIHEKOU FENGSHUN PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: WINSUNNY UNION PHARMACEUTICAL CO., LTD.

Effective date: 20110920

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20110920

Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee after: Meihekou Feng Shun Pharmaceutical Co., Ltd.

Address before: 135000 north section of Meihekou, Jilin, Zhujianglu Road

Patentee before: Wansheng Lianhe Pharmaceutical Co., Ltd.

C56 Change in the name or address of the patentee

Owner name: JILIN CHANGSHUN PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: MEIHEKOU FENGSHUN PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee after: JILIN CHANGSHUN PHARMACEUTICAL CO., LTD.

Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee before: Meihekou Feng Shun Pharmaceutical Co., Ltd.

C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee after: Hung Tai Pharmaceutical (China) Co., Ltd.

Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee before: JILIN CHANGSHUN PHARMACEUTICAL CO., LTD.

CB03 Change of inventor or designer information

Inventor after: Jiang Yanyan

Inventor after: Gong Jing

Inventor after: Wang Jianhui

Inventor before: Wang Jianhui

COR Change of bibliographic data
CP01 Change in the name or title of a patent holder

Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee after: Hong ho Pharmaceutical Company Limited

Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou

Patentee before: Hung Tai Pharmaceutical (China) Co., Ltd.